Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Curvebeam AI Ltd. ( (AU:CVB) ) has shared an update.
CurveBeam AI has appointed U.S.-based orthopaedic industry veteran Patrick Fisher as an independent non-executive director, adding extensive leadership experience from Orthofix, Stryker and Wright Medical. Fisher’s background in global orthopaedic markets, capital equipment deployment and surgeon engagement is expected to support the broader rollout of CurveBeam’s weight-bearing CT technology.
The company’s chair said Fisher’s appointment strengthens strategic capabilities in the key U.S. growth market as CurveBeam executes its next phase of commercial expansion. Fisher, who will receive a mix of cash fees and time-vested share rights, highlighted plans to help drive partnerships, market adoption and sustained growth in the U.S. and internationally.
The most recent analyst rating on (AU:CVB) stock is a Hold with a A$0.15 price target. To see the full list of analyst forecasts on Curvebeam AI Ltd. stock, see the AU:CVB Stock Forecast page.
More about Curvebeam AI Ltd.
CurveBeam AI Limited is a medical imaging company that develops, manufactures and sells specialised CT scanners combined with AI-enabled SaaS clinical assessment tools for musculoskeletal care. Its flagship HiRise system performs weight-bearing and traditional CT scans, targeting orthopaedic and related markets from bases in Melbourne and Hatfield, Pennsylvania.
Average Trading Volume: 851,116
Technical Sentiment Signal: Sell
Current Market Cap: A$27.71M
See more insights into CVB stock on TipRanks’ Stock Analysis page.